Cinqair (reslizumab) is an interleukin-5 antagonist monoclonal antibody (IgG4 kappa).
Cinqair is specifically indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype.
Cinqair is supplied as a solution for intravenous administration.
Submit your review
Adverse effects associated with the use of Cinqair may include, but is not limited to, the following:
Cinqair comes with a black box warning of the potential for anaphylaxis.
The recommended dose is 3 mg/kg once every 4 weeks administered by intravenous infusion over 20-50 minutes.